Gobezie Reuben, Millett Peter J, Sarracino David S, Evans Christopher, Thornhill Thomas S
Case Center for Proteomics, Department of Orthopaedic Surgery, Case Western Reserve University, 11000 Euclid Avenue, Cleveland, OH 44106, USA.
J Am Acad Orthop Surg. 2006 Jun;14(6):325-32. doi: 10.5435/00124635-200606000-00002.
The study of both DNA and protein technologies has been marked by unprecedented achievement over the last decade. The completion of the Human Genome Project in 2003 is representative of a new era in genomics; likewise, proteomics research, which has revolutionized the way we study disease, offers the potential to unlock many of the pathophysiologic mechanisms underlying the clinical problems encountered by orthopaedic surgeons. These new fields are extending our approach to and investigation of the etiology and progression of musculoskeletal disorders, notably rheumatoid arthritis and osteoarthritis. Advances in proteomics technology may lead to the development of biomarkers for both rheumatoid arthritis and osteoarthritis. Such biomarkers would improve early detection of these diseases, measure response to treatment, and expand knowledge of disease pathogenesis.
在过去十年中,DNA技术和蛋白质技术的研究都取得了前所未有的成就。2003年人类基因组计划的完成代表了基因组学的一个新时代;同样,蛋白质组学研究彻底改变了我们研究疾病的方式,为揭示骨科医生所面临临床问题背后的许多病理生理机制提供了可能。这些新领域正在拓展我们对肌肉骨骼疾病(尤其是类风湿性关节炎和骨关节炎)病因及进展的研究方法和调查手段。蛋白质组学技术的进步可能会促成类风湿性关节炎和骨关节炎生物标志物的开发。此类生物标志物将改善这些疾病的早期检测、衡量治疗反应并拓展对疾病发病机制的认识。